Listar MD - Artículos por autor "Margelí, Mireia"
Mostrando ítems 1-4 de 4
-
Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
Aparicio, Jorge; Maroto, Pablo; García del Muro, Xavier; Sánchez-Muñoz, Alfonso
; Guma, Josep; Margelí, Mireia; Sáenz, Alberto; Sagastibelza, Naiara; Castellano, Daniel; Arranz-Arija, José Ángel; Hervás, David; Bastús, Romá; Fernández-Aramburo, Antonio; Sastre, Javier; Terrasa, Josefa; Lopez-Brea, Marta; Dorca, Joan; Almenar, Daniel; Carles, J.; Hernández, Álvaro; Germá-Lluch, José Ramón[et al.] (Elsevier, 2014-09-10)
Background: We aimed to analyze prognostic factors for relapse in stage I seminoma managed by either active surveillance or adjuvant chemotherapy, and to describe the long-term patterns of recurrence in both groups. Patients ... -
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
González-Billalabeitia, Enrique; Castellano, Daniel; Sobrevilla, Nora; Guma, Josep; Hervás, David; Luengo, María I.; Aparicio, Jorge; Sánchez-Muñoz, Alfonso; Mellado, Begoña; Sáenz, Alberto; Valverde, Claudia; Fernández, Antonio; Margelí, Mireia; Durán, Ignacio; Fernández, Sara; Sastre, Javier; Ros, Silverio; Maroto, Pablo; Manneh, Ray; Cerezuela, Pablo; Carmona-Bayonas, Alberto; Ayala de la Peña, Francisco; Aguilar, José Luis; Rivera, Samuel; García del Muro, Xavier; Germá-Lluch, José Ramón[et al.] (Oxford Academic, 2017-01-26)
Background: Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer. Results: ... -
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; Martínez-García, M.; Ramos-Boyero, Manuel; O'Connor, Miriam; De-la-Cruz-Merino, Luis; Santaballa-Bertrán, Ana; Martínez-Jáñez, Noelia; Moreno-Antón, Fernando; Fernández, Isaura; Alarcón, Jesús Damián; Virizuela-Echaburu, Javier Antonio; De-la-Haba-Rodríguez, Juan Rafael; Sánchez- Rovira, P; González-Cortijo, Lucía; Margelí, Mireia; Sánchez-Muñoz, Alfonso; Antón, A.; Casas, María Isabel; Bezares, Susana; Rojo, Federico[et al.] (Elsevier, 2022)
Background: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast ... -
Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
Aparicio, Jorge; Maroto, Pablo; García del Muro, Xavier; Guma, Josep; Sánchez-Muñoz, Alfonso; Margelí, Mireia; Domenech, Montserrat; Bastús, Romá; Fernández, Antonio; Lopez-Brea, Marta; Terrassa, Josefa; Meana, Andrés; Martínez del Prado, Purificación; Sastre, Javier; Satrustegui, Juan J.; Girones, Regina; Robert, Lidia; Germa, José R.[et al.] (Editorial Roster. ASCO publications, 2011-10)
Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both the risk of relapse and the proportion of patients receiving adjuvant chemotherapy ...